{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:49:17Z","timestamp":1762177757077,"version":"3.44.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Mantle cell lymphoma (MCL) is a rare, aggressive non-Hodgkin lymphoma (NHL) that can affect the kidneys. In this research, we described a very rare case of secondary membranous nephropathy (MN) associated with MCL. A 67-year-old man manifested with impaired renal function and nephrotic syndrome (NS). Kidney biopsy revealed atypical MN and MCL cell infiltration. After eight rounds of modified R-CHOP therapy, which includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone, the patient achieved complete remission, accompanied by improved renal function and a reduction in proteinuria. This case demonstrates the precise diagnosis and treatment of the primary disease, which can lead to favorable outcomes.<\/jats:p>","DOI":"10.3389\/fmed.2025.1627010","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:27:45Z","timestamp":1755235665000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Membranous nephropathy associated with mantle cell lymphoma: a rare case"],"prefix":"10.3389","volume":"12","author":[{"given":"Mian","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luxi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanquan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMra2202672","article-title":"Mantle-cell Lymphoma","volume":"386","author":"Armitage","year":"2022","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/imj.14268","article-title":"Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma","volume":"49","author":"Cheah","year":"2019","journal-title":"Intern Med J"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41581-022-00564-1","article-title":"Membranous nephropathy: new pathogenic mechanisms and their clinical implications","volume":"18","author":"Hoxha","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1097\/IMNA-D-23-00014","article-title":"Diagnosis and treatment of membranous nephropathy in integrative medicine","volume":"11","author":"Bi Jingru","year":"2024","journal-title":"Integrat Med Nephrol Androl"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e00007","DOI":"10.1097\/IMNA-D-23-00007","article-title":"IgG4-related disease with IgG1-dominant membranous nephropathy: a rare case report","volume":"10","author":"Duan","year":"2023","journal-title":"Integrat Med Nephrol Androl"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"593288","DOI":"10.3389\/fimmu.2021.593288","article-title":"Autoantibodies in the diagnosis, monitoring, and treatment of membranous nephropathy","volume":"12","author":"Tesar","year":"2021","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1034\/j.1600-0609.2001.5790493.x","article-title":"Kidney involvement and renal manifestations in non-Hodgkin's lymphoma and lymphocytic leukemia: a retrospective study in 700 patients","volume":"67","author":"Da'as","year":"2001","journal-title":"Eur J Haematol"},{"key":"ref8","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3760\/cma.j.issn.0253-2727.2022.07.001","article-title":"Zhonghua Xue Ye Xue Za Zhi. Hematology oncology Committee of China Anti Cancer a, Society of Hematology at Chinese medical a, Union for China Lymphoma Investigator at Chinese Society of Clinical O: [the guideline of the diagnosis and treatment of mantle cell lymphoma in China (2022)]","volume":"43","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Eastern cooperative oncology G et al: recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s11255-012-0210-4","article-title":"Membranoproliferative glomerulonephritis, mantle cell lymphoma infiltration, and acute kidney injury","volume":"45","author":"Lubas","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3109\/0886022X.2014.883905","article-title":"Minimal change disease associated with newly diagnosed mantle cell lymphoma","volume":"36","author":"Khow","year":"2014","journal-title":"Ren Fail"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5414\/CNCS109036","article-title":"Antineutrophil cytoplasmic antibody-positive pauci-immune glomerulonephritis associated with mantle cell lymphoma","volume":"5","author":"Miyata","year":"2017","journal-title":"Clin Nephrol Case Stud"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"759279","DOI":"10.3389\/fmed.2021.759279","article-title":"Case report: a rare case of lupus nephritis associated with mantle cell Lymphoma","volume":"8","author":"Bao","year":"2021","journal-title":"Front Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000187221","article-title":"Membranous nephropathy associated with nodular sclerosing Hodgkin's disease","volume":"63","author":"Hotta","year":"1993","journal-title":"Nephron"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1159\/000188411","article-title":"Membranous nephropathy in Hodgkin's disease in complete remission","volume":"68","author":"Gomez-Campdera","year":"1994","journal-title":"Nephron"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0002-9343(86)90049-5","article-title":"Glomerular lesions in lymphomas and leukemias","volume":"80","author":"Dabbs","year":"1986","journal-title":"Am J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"E22","DOI":"10.1053\/ajkd.2002.33413","article-title":"Primary cerebral lymphoma and membranous nephropathy: a still unreported association","volume":"39","author":"Strippoli","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"903315","DOI":"10.3389\/fimmu.2022.903315","article-title":"Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder","volume":"13","author":"Nie","year":"2022","journal-title":"Front Immunol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ekir.2021.12.020","article-title":"A diverse Spectrum of immune complex- and complement-mediated kidney diseases is associated with mantle cell Lymphoma","volume":"7","author":"Andeen","year":"2022","journal-title":"Kidney Int Rep"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12882-024-03665-0","article-title":"Diagnosis and treatment of secondary nephrotic syndrome with rash as the first symptom: a case report","volume":"25","author":"Qin","year":"2024","journal-title":"BMC Nephrol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"sfaf101","DOI":"10.1093\/ckj\/sfaf101","article-title":"Malignancies and glomerulonephritis: when to suspect and when to screen?","volume":"18","author":"Murt","year":"2025","journal-title":"Clin Kidney J"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1007\/s12033-023-00934-5","article-title":"THSD7A as a promising biomarker for membranous nephrosis","volume":"66","author":"Jiang","year":"2024","journal-title":"Mol Biotechnol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1053\/j.ajkd.2020.10.009","article-title":"Membranous nephropathy: Core curriculum 2021","volume":"77","author":"Alsharhan","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41401-023-01148-w","article-title":"Sirtuin 6 protects against podocyte injury by blocking the renin-angiotensin system by inhibiting the Wnt1\/beta-catenin pathway","volume":"45","author":"Miao","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bph.16219","article-title":"Lactobacillus species ameliorate membranous nephropathy through inhibiting the aryl hydrocarbon receptor pathway via tryptophan-produced indole metabolites","volume":"181","author":"Miao","year":"2024","journal-title":"Br J Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.freeradbiomed.2023.07.014","article-title":"Oxidative stress and inflammation are mediated via aryl hydrocarbon receptor signalling in idiopathic membranous nephropathy","volume":"207","author":"Wang","year":"2023","journal-title":"Free Radic Biol Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1391675","DOI":"10.3389\/fphar.2024.1391675","article-title":"Efficacy and safety of Chinese herbal medicines combined with biomedicine in the treatment of idiopathic membranous nephropathy: a systematic review and network meta-analysis","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell Lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1200\/JCO.21.01797","article-title":"Ibrutinib with rituximab in first-line treatment of older patients with mantle cell Lymphoma","volume":"40","author":"Jain","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"JCO2500146","DOI":"10.1200\/JCO-25-00146","article-title":"Mantle cell Lymphoma: optimal treatment with Bruton tyrosine kinase-targeted approaches","author":"Eyre","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus Venetoclax for the treatment of mantle-cell Lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","article-title":"Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy","volume":"57","author":"Goebeler","year":"2016","journal-title":"Leuk Lymphoma"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1627010\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:27:47Z","timestamp":1755235667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1627010\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":34,"alternative-id":["10.3389\/fmed.2025.1627010"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1627010","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"article-number":"1627010"}}